The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure. Permutation trial tests in patients in long-term treatment with bumetanide.
The additive natriuretic effect of a single dose of bendroflumethiazide, 5 mg., has been studied in patients with advanced congestive heart failure in long-term treatment with bumetanide, 4 mg., daily. Three permutation trial tests were performed including six patients each. In the first trial, the response to supplementary bendroflumethiazide, 5 mg., was definitely superior to that of additional bumetanide, 4 mg., in terms of renal output of sodium, chloride, potassium, water, and osmolar clearance. In the second trial, a similar pattern was found in patients receiving a combination of bumetanide, 4 mg., and spironolactone, 100 mg., daily. The third trial compared the effects of bendroflumethiazide, 5 mg., plus bumetanide, 4 mg.; of bendroflumethiazide, 5 mg.; and of bumetanide, 4 mg. In terms of natriuresis and chloruresis, the response to the combination of two drugs was significantly larger than the sum of the effects of other treatments. It is concluded that the combined effects of the drugs represent a supra-additive effect addition for sodium and chloride. A tentative explanation of the mechanism of interaction in terms of inhibition of renal tubular supplementary spironolactone, involve a tendency to development of hypokalemia, hypochloremia, and alkalosis, it is recommended that supplementary use of bendroflumethiazide in this setting is combined with the administration of potassium chloride or potassium-saving diuretics.
D000328:Adult; D001539:Bendroflumethiazide / Q000008:administration & dosage* / Q000494:pharmacology; D001565:Benzoates / Q000008:administration & dosage / Q000494:pharmacology; D002082:Butylamines / Q000008:administration & dosage / Q000494:pharmacology; D002712:Chlorides / Q000652:urine; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy; D003401:Creatine / Q000097:blood / Q000652:urine; D004077:Digoxin / Q000008:administration & dosage; D004232:Diuretics / Q000008:administration & dosage* / Q000494:pharmacology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009318:Natriuresis / Q000187:drug effects*; D009399:Nephrons / Q000187:drug effects; D010919:Placebos; D011188:Potassium / Q000652:urine; D011189:Potassium Chloride / Q000627:therapeutic use; D012964:Sodium / Q000652:urine; D013148:Spironolactone / Q000008:administration & dosage; D013449:Sulfonamides
D001565:Benzoates; D002082:Butylamines; D002712:Chlorides; D004232:Diuretics; D010919:Placebos; D013449:Sulfonamides; D013148:Spironolactone; D001539:Bendroflumethiazide; D011189:Potassium Chloride; D004077:Digoxin; D012964:Sodium; D003401:Creatine; D011188:Potassium